ALB and neoplasm: The long-linker-based agents, 177Lu-Alb-L4 (tumor AUC0-192h of 12,857 ± 1469%ID/g.h) and 177Lu-Alb-L5 (tumor AUC0-192h of 18,842 ± 1693%ID/g.h) demonstrated a > 2-fold improvement in tumor uptake compared to 177Lu-L14.